U.S. markets closed
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • Dow 30

    34,764.82
    +506.50 (+1.48%)
     
  • Nasdaq

    15,052.24
    +155.40 (+1.04%)
     
  • Russell 2000

    2,259.04
    +40.48 (+1.82%)
     
  • Crude Oil

    73.24
    -0.06 (-0.08%)
     
  • Gold

    1,742.80
    -36.00 (-2.02%)
     
  • Silver

    22.65
    -0.22 (-0.96%)
     
  • EUR/USD

    1.1743
    +0.0047 (+0.40%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • GBP/USD

    1.3722
    +0.0103 (+0.75%)
     
  • USD/JPY

    110.2950
    +0.5170 (+0.47%)
     
  • BTC-USD

    44,623.06
    +1,530.88 (+3.55%)
     
  • CMC Crypto 200

    1,119.18
    +10.26 (+0.92%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Better Buy: Vertex vs. CRISPR

·4 min read
Better Buy: Vertex vs. CRISPR
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.